EC Number   |
Application |
Reference |
|---|
   3.1.1.25 | medicine |
incubation of serum or high density lipoprotein from healthy subjects with very low density lipoprotein significantly decreases serum paraoxonase 1 lactonase or arylesterase activities by up to 11% or 24%, and HDL-associated paraoxonase 1 lactonase or arylesterase activities by up to 32% or 46%, respectively. Very low density lipoprotein also inhibits recombinant paraoxonase 1 lactonase or arylesterase activities by up to 20% or 42%, respectively. Bezafibrate therapy to three hypertriglyceridemic patients (400 mg/day, for one month) significantly decreased serum triglyceride concentration by 67%, and increased serum high density lipoproteincholesterol levels by 48%. Paraoxonase 1 arylesterase or paraoxonase activities in the patients' high density lipoprotein fractions after drug therapy are significantly increased by 86-88%, as compared to paraoxonase 1 activities before treatment. High density lipoprotein-paraoxonase 1 protein levels significantly increased after bezafibrate therapy |
729341 |
| 3.1.1.25 | medicine |
PON1 overexpression is associated with decreased diabetes-induced macrophage oxidative stress, decreased diabetes development, and decreased mortality |
692438 |
| 3.1.1.25 | synthesis |
production of pantoic acid, which is used as a Vitamin B2-complex, production of D- and L-pantolactones, which are used as chiral intermediates in chemical synthesis |
660015 |
| 3.1.1.25 | synthesis |
the recombinant enzyme is a highly efficient biocatalyst for asymmetric synthesis of chiral compounds |
713789 |
